A 2022 review analyzes six potential antigens targeted by CAR-T cells in CTCL, namely CD4, CD47, CD30, CCR4, TAG-72, and CD37 and examines the limitations of CAR T cell therapy [126]. This evidence concerns the gene CD4 and primary cutaneous T-cell non-Hodgkin lymphoma.